Madoka Mori‐Yoshimura

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial

Michael G. Hanna, Umesh A. Badrising, Olivier Benvéniste et al. · The Lancet Neurology · 2019 · 133 citations · Full text

Life Sciences, Clinical Sciences, Immunology +16

Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials

Jordi Díaz‐Manera, Roberto Fernández‐Torrón, Jaume Llauger et al. · Journal of Neurology Neurosurgery & Psychiatry · 2018 · 117 citations · Full text

Medicine, Neurology, Radiology +17

The Clinical Outcome Study for dysferlinopathy

Elizabeth Harris, Catherine L. Bladen, Anna Mayhew et al. · Neurology Genetics · 2016 · 111 citations · Full text

Medicine, Genetics, Neurology +15

Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies

Wen‐Chen Liang, Akinori Uruha, Shigeaki Suzuki et al. · Lara D. Veeken · 2016 · 91 citations · Full text

Medicine, Pathology, Pediatrics +17

Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy)

Harumasa Nakamura, En Kimura, Madoka Mori‐Yoshimura et al. · Orphanet Journal of Rare Diseases · 2013 · 76 citations · Full text

Life Sciences, Genetics, Molecular Genetics +13